Light-responsive nanomedicine for cancer immunotherapy
Acta Pharmaceutica Sinica B · 2023-06 · 13 (6) · 2346-2368
DOI: 10.1016/j.apsb.2023.05.016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2023-06. Verfasst von Weirong Kang und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong, Hong Kong, China. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Grants Council, University Grants Committee, University Grants Committee.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Pharmaceutical Biotechnology, the University of Hong Kong, Hong Kong, China.
- Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, the University of Hong Kong, Hong Kong, China.
- Laboratory of Molecular Engineering and Nanomedicine, Dr. Li Dak-Sum Research Centre, the University of Hong Kong, Hong Kong, China.
Förderung
- Research Grants Council, University Grants Committee
- University Grants Committee
Zitieren
APA
Kang, W., Liu, Y., & Wang, W. (2023). Light-responsive nanomedicine for cancer immunotherapy. Acta Pharmaceutica Sinica B, 13(6), 2346-2368. https://doi.org/10.1016/j.apsb.2023.05.016
Vancouver
Kang W, Liu Y, Wang W. Light-responsive nanomedicine for cancer immunotherapy. Acta Pharmaceutica Sinica B. 2023;13(6):2346-2368. doi:10.1016/j.apsb.2023.05.016
BibTeX
@article{Kang2023,
author = {Kang, Weirong and Liu, Yuwei and Wang, Weiping},
title = {Light-responsive nanomedicine for cancer immunotherapy},
journal = {Acta Pharmaceutica Sinica B},
year = {2023},
volume = {13},
number = {6},
pages = {2346--2368},
doi = {10.1016/j.apsb.2023.05.016}
}
EUVIMED